GlassScriptPhysician profile
Samar Mahmood
NPI 1669545943
$8,665.51
in general payments reported to CMS, 2019-2025
38 companies · $1,723 in 2025
The $1,723 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,613 · 2020: $635 · 2021: $1,039 · 2022: $1,540 · 2023: $1,276 · 2024: $840 · 2025: $1,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,838.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,498.23 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $644.56 | 2019-2025 | Rexulti, Abilify Mycite |
| Neurocrine Biosciences, INC. | $588.72 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $534.60 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $509.06 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $414.68 | 2019-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $414.10 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $413.71 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $404.67 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $361.99 | 2022-2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $308.44 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $283.60 | 2019-2023 | Trintellix |
| Allergan, INC. | $262.56 | 2019-2020 | |
| Almatica Pharma LLC | $237.44 | 2022-2023 | Sertraline Hcl, Loreev Xr |
| Indivior INC. | $198.42 | 2019-2024 | Perseris |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.